Targeted In VivoGeneration of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform

CAR T cell therapies have revolutionized the treatment of B cell malignancies. Ex vivoCAR manufacturing is complex, costly, and cumbersome, prompting efforts that develop shorter manufacturing and allogeneic or “universal donor” strategies. Conventional ex vivoCAR T cell therapy is not widely accessible and financial burdens to patients further hinder access to care. Furthermore, recent data show that CAR T product efficacy is correlated with reduced ex vivomanipulation of cells.